You have full text access to this OnlineOpen article

Cancer

Cover image for Vol. 117 Issue 3

1 February 2011

Volume 117, Issue 3

Pages 437–656

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
    4. You have free access to this content
  2. Commentaries

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    1. You have full text access to this OnlineOpen article
      Cancer: More of polygenic disease and less of multiple mutations? A quantitative viewpoint (pages 440–445)

      Anders Bredberg

      Article first published online: 22 SEP 2010 | DOI: 10.1002/cncr.25440

      Some quantitative aspects of carcinogenesis are outlined, suggesting that a network regulatory mechanism controls overt cancer disease. Understanding this network may give us opportunities for highly potent therapeutic tools.

  3. Editorials

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    1. You have full text access to this OnlineOpen article
      The signal of suicide rates seen from a distance in patients with pancreatic cancer (pages 446–448)

      Donna B. Greenberg

      Article first published online: 22 SEP 2010 | DOI: 10.1002/cncr.25419

      Although suicide is rare in patients with pancreatic cancer, the higher rate of suicide signals that the anguish of clinical depression is common. Older men, more alone, with a history of substance abuse and depression, soon after diagnosis, are more at risk for suicide; attention to psychiatric syndromes is an integral part of cancer care.

    2. You have full text access to this OnlineOpen article
      Reducing ovarian cancer death rates through screening (pages 449–450)

      Patricia Hartge

      Article first published online: 13 DEC 2010 | DOI: 10.1002/cncr.25622

      In this issue, Havrilesky and colleagues argue that the biologic diversity of ovarian cancer means that it will be even harder than expected to save lives through screening. Empirical results from the current randomized clinical trials will provide the strongest evidence about the potential for reducing ovarian cancer death through screening.

    3. You have full text access to this OnlineOpen article
      Mucinous ovarian carcinoma: Slippery business (pages 451–453)

      Robert A. Soslow

      Article first published online: 15 SEP 2010 | DOI: 10.1002/cncr.25453

      The belief that ovarian mucinous carcinomas are common, clinically unpredictable and often associated with pseudomyxoma peritonei is outmoded. A study from the Gynecologic Oncology Group, published in this edition, makes the case that high-stage mucinous tumors involving the ovary frequently represent metastases from extraovarian primary sites, are often misdiagnosed, and behave virulently.

  4. Review Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    1. You have full text access to this OnlineOpen article
      Treatment of pituitary neoplasms with temozolomide : A review (pages 454–462)

      Luis V. Syro, Leon D. Ortiz, Bernd W. Scheithauer, Ricardo Lloyd, Queenie Lau, Ricardo Gonzalez, Humberto Uribe, Michael Cusimano, Kalman Kovacs and Eva Horvath

      Article first published online: 15 SEP 2010 | DOI: 10.1002/cncr.25413

      Recent reports have documented the efficacy of temozolomide in the treatment of pituitary adenomas and carcinomas and the role of O6-methylguanine-DNA methyltransferase (MGMT) immunoexpression, which has been correlated with response to temozolomide treatment. The authors reviewed all published cases and to determine the demographic characteristics, types of tumor, MGMT immunoexpression, response to therapy, and indications for temozolomide treatment.

  5. Original Articles

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    1. Disease Site

      Breast Disease
      You have full text access to this OnlineOpen article
      Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine : From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 (pages 463–471)

      Jarrod P. Holmes, Guy T. Clifton, Ritesh Patil, Linda C. Benavides, Jeremy D. Gates, Alexander Stojadinovic, Elizabeth A. Mittendorf, Sathibalan Ponniah and George E. Peoples

      Article first published online: 15 SEP 2010 | DOI: 10.1002/cncr.25586

      A booster inoculation of the HER-2/neu E75 peptide vaccine is safe and effective at maintaining peptide-specific immunity. Results suggest that the booster should be given at 6 months from completion of the primary vaccination series for optimal effect.

    2. You have full text access to this OnlineOpen article
      High genomic grade index associated with poor prognosis for lymph node-negative and estrogen receptor-positive breast cancers and with good response to chemotherapy (pages 472–479)

      Yasuto Naoi, Kazuki Kishi, Tomonori Tanei, Ryo Tsunashima, Naoomi Tominaga, Yosuke Baba, Seung Jin Kim, Tetsuya Taguchi, Yasuhiro Tamaki and Shinzaburo Noguchi

      Article first published online: 27 SEP 2010 | DOI: 10.1002/cncr.25626

      Genomic grade index is a powerful prognostic factor for lymph node-negative and estrogen receptor (ER)-positive tumors treated with adjuvant hormonal therapy alone, and high genomic grade index tumors are more likely to respond to chemotherapy. Genomic grade index also appears to be very useful for decision making regarding the need for adjuvant chemotherapy for lymph node-negative and ER-positive breast cancers.

    3. Gastrointestinal Disease
      You have full text access to this OnlineOpen article
      Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer (pages 480–491)

      Xiaoqun Dong, Hongwei Tang, Kenneth R. Hess, James L. Abbruzzese and Donghui Li

      Article first published online: 15 SEP 2010 | DOI: 10.1002/cncr.25612

      The authors demonstrated that polymorphic variants of glucose metabolic genes are associated with overall survival, tumor response to therapy, tumor resectability, and tumor stage in pancreatic cancer. These genetic variants may serve as biomarkers for future genomically tailored pancreatic cancer therapy.

    4. You have full text access to this OnlineOpen article
      Evidence for an hMSH3 defect in familial hamartomatous polyps (pages 492–500)

      Sherry C. Huang, Jeffrey K. Lee, E. Julieta Smith, Ryan T. Doctolero, Akihiro Tajima, Stayce E. Beck, Noel Weidner and John M. Carethers

      Article first published online: 15 SEP 2010 | DOI: 10.1002/cncr.25445

      Some familial hamartomatous polyps transform into colonic adenocarcinoma. A genetic signature from polyp epithelium indicates that loss of the DNA mismatch repair protein hMSH3 may be a driving mechanism for transformation.

    5. Genitourinary Disease
      You have full text access to this OnlineOpen article
      Sunitinib in metastatic renal cell carcinoma patients with brain metastases (pages 501–509)

      Martin E. Gore, Subramanian Hariharan, Camillo Porta, Sergio Bracarda, Robert Hawkins, Georg A. Bjarnason, Stéphane Oudard, Se-Hoon Lee, Giacomo Carteni, Alejandra Nieto, Jinyu Yuan and Cezary Szczylik

      Article first published online: 22 SEP 2010 | DOI: 10.1002/cncr.25452

      Three hundred twenty-one patients with brain metastases from RCC were enrolled in a global, open-label, expanded access program of sunitinib. The safety profile of sunitinib was comparable to that in the general metastatic RCC population, and sunitinib showed evidence of antitumor activity.

    6. You have full text access to this OnlineOpen article
      Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer : Long-term results from Dana-Farber Cancer Institute study 94-153 (pages 510–516)

      Mark D. Hurwitz, Jorgen L. Hansen, Savina Prokopios-Davos, Judith Manola, Qian Wang, Bruce A. Bornstein, Kullervo Hynynen and Irving D. Kaplan

      Article first published online: 30 SEP 2010 | DOI: 10.1002/cncr.25619

      Results from a phase 2 study that assessed the use of hyperthermia combined with radiation and androgen suppression indicated that hyperthermia was associated with a significant improvement in 2-year disease-free survival compared with historic controls (84% vs 64%, respectively). At a median follow-up of 70 months, the 7-year overall survival rate was 94%.

    7. You have full text access to this OnlineOpen article
      Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients (pages 517–525)

      William K. Oh, Roberto Vargas, Susanna Jacobus, Kim Leitzel, Meredith M. Regan, Peter Hamer, Karen Pierce, Sheryl Brown-Shimer, Walter Carney, Suhail M. Ali, Philip W. Kantoff and Allan Lipton

      Article first published online: 22 SEP 2010 | DOI: 10.1002/cncr.25394

      Improved prognostic markers in prostate advanced cancer are needed. Increased levels of the biomarker tissue inhibitor of metalloproteinase-1 predict decreased survival in metastatic castration-resistant prostate cancer patients, independent of known prognostic markers.

    8. You have full text access to this OnlineOpen article
      A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer : Results from Cancer and Leukemia Group B Study 90006 (pages 526–533)

      Joel Picus, Susan Halabi, W. Kevin Kelly, Nicholas J. Vogelzang, Young E. Whang, Ellen B. Kaplan, Walter M. Stadler, Eric J. Small and for Cancer and Leukemia Group B

      Article first published online: 22 SEP 2010 | DOI: 10.1002/cncr.25421

      The authors report on the use of bevacizumab added to docetaxel-based chemotherapy for castrate-resistant prostate cancer. A very high response rate was observed, and toxicity also was noted.

    9. You have full text access to this OnlineOpen article
      Hypothyroidism in patients with renal cell carcinoma : Blessing or curse? (pages 534–544)

      Manuela Schmidinger, Ursula M. Vogl, Marija Bojic, Wolfgang Lamm, Harald Heinzl, Andrea Haitel, Martin Clodi, Gero Kramer and Christoph C. Zielinski

      Article first published online: 15 SEP 2010 | DOI: 10.1002/cncr.25422

      The current results indicated that hypothyroidism may serve as a predictive marker for treatment outcome. Thus, the interpretation of hypothyroidism as an unwanted side effect during treatment with sunitinib and sorafenib should be reconsidered.

    10. Gynecologic Oncology
      You have full text access to this OnlineOpen article
      Development of an ovarian cancer screening decision model that incorporates disease heterogeneity : Implications for potential mortality reduction (pages 545–553)

      Laura J. Havrilesky, Gillian D. Sanders, Shalini Kulasingam, Junzo P. Chino, Andrew Berchuck, Jeffrey R. Marks and Evan R. Myers

      Article first published online: 13 DEC 2010 | DOI: 10.1002/cncr.25624

      A decision model predicted that annual screening for ovarian cancer using the best currently available tests was likely to result in a modest mortality reduction. Incorporation into the model of recent histopathologic data suggesting 2 phenotypes of ovarian cancer resulted in a lower predicted mortality reduction because of the more frequent diagnosis of indolent cancers at earlier stages.

    11. You have full text access to this OnlineOpen article
      Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal : A Gynecologic Oncology Group Study (pages 554–562)

      Richard J. Zaino, Mark F. Brady, Subodh M. Lele, Helen Michael, Benjamin Greer and Michael A. Bookman

      Article first published online: 22 SEP 2010 | DOI: 10.1002/cncr.25460

      A prospective randomized trial of stage III and IV ovarian carcinoma provided an opportunity to estimate the frequency of mucinous tumors, diagnostic reproducibility, and clinical outcomes. Forty-four cases were reviewed by three pathologists and classified as primary or metastatic. Reproducibility of interpretations was high, with unanimity of opinion in 30 of 44 (68%) cases, and most were judged to be metastatic to the ovary. Overall survival was less than that for women with serous carcinoma (14 vs 42 months, P < 0.001). Advanced stage mucinous carcinoma of the ovary is rare and is associated with poor overall survival..

    12. Head and Neck Disease
      You have full text access to this OnlineOpen article
      Craniofacial resection for malignant tumors involving the skull base in the elderly : An international collaborative study (pages 563–571)

      Ian Ganly, Snehal G. Patel, Bhuvanesh Singh, Dennis H. Kraus, Giulo Cantu, Dan M. Fliss, Luiz P. Kowalski, Carl Snyderman and Jatin P. Shah

      Article first published online: 24 SEP 2010 | DOI: 10.1002/cncr.25390

      The authors examined a large cohort of patients accumulated from multiple institutions that had experience in craniofacial surgery with the objective of reporting outcomes and complications from craniofacial resection in the elderly. Craniofacial resection for malignant skull base tumors in the elderly was associated with increased mortality, complications, and poorer outcome compared with patients aged <70 years.

    13. Hematologic Malignancies
      You have full text access to this OnlineOpen article
      Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia : A randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor (pages 572–580)

      Jorge Cortes, Alfonso Quintás-Cardama, Dan Jones, Farhad Ravandi, Guillermo Garcia-Manero, Srdan Verstovsek, Charles Koller, Jody Hiteshew, Jenny Shan, Susan O'Brien and Hagop Kantarjian

      Article first published online: 30 SEP 2010 | DOI: 10.1002/cncr.25438

      Therapeutic strategies to eradicate minimal residual disease are warranted in chronic myelogenous leukemia (CML). The authors present the first report testing, in a randomized manner, the long-term activity and tolerability of adding pegylated interferon alpha-2b to high-dose imatinib therapy in patients with CML in chronic phase. Although no significant differences were observed in the rates of molecular response between the treatment arms, this trial provides the foundation for future clinical trials intended to eradicate minimal residual disease in CML.

    14. You have full text access to this OnlineOpen article
      Primary cardiac lymphoma : An analysis of presentation, treatment, and outcome patterns (pages 581–589)

      Adam Petrich, Soung Ick Cho and Henny Billett

      Article first published online: 4 OCT 2010 | DOI: 10.1002/cncr.25444

      The authors present the largest analysis of PCL to date. Our data demonstrate that PCL is now more frequently diagnosed premortem and appears to have reasonable response rates. Lack of LV involvement and the presence of arrhythmias are associated with improved survival.

    15. Lung Disease
      You have full text access to this OnlineOpen article
      Promoter methylation of the RGC32 gene in nonsmall cell lung cancer (pages 590–596)

      Dong Sun Kim, Ji Yun Lee, Su Man Lee, Jin Eun Choi, Sukki Cho and Jae Yong Park

      Article first published online: 22 SEP 2010 | DOI: 10.1002/cncr.25451

      RGC32 methylation was found in 45 of 173 nonsmall cell lung cancers (26.0%) and was related to the gene expression. The effect of RGC32 methylation on prognosis was significantly different according to TP53 mutational status.

    16. You have full text access to this OnlineOpen article
      Time for reappraisal of extracranial treatment options? : Synchronous brain metastases from nonsmall cell lung cancer (pages 597–605)

      Joline S.W. Lind, Frank J. Lagerwaard, Egbert F. Smit, Pieter E. Postmus, Ben J. Slotman and Suresh Senan

      Article first published online: 24 SEP 2010 | DOI: 10.1002/cncr.25416

      For selected patients with synchronous brain metastases (BM) from NSCLC as the only sign of stage IV disease, who are eligible to undergo stereotactic radiotherapy or surgical resection of BM, radical thoracic treatment may be justified, even in the presence of stage III thoracic disease.

    17. You have full text access to this OnlineOpen article
      Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers (pages 606–617)

      Kristy L. Richards, Baili Zhang, Menghong Sun, Wenli Dong, Jennifer Churchill, Linda L. Bachinski, Charmaine D. Wilson, Keith A. Baggerly, Guosheng Yin, D. Neil Hayes, Ignacio I. Wistuba and Ralf Krahe

      Article first published online: 13 OCT 2010 | DOI: 10.1002/cncr.25472

      The transcription factor TCF21, which is involved in mesenchymal-to-epithelial differentiation, is hypermethylated and down-regulated in >80% of nonsmall cell lung cancer (NSCLC) samples, which makes TCF21 a potential candidate methylation biomarker for early-stage NSCLC screening. TCF21 hypermethylation in a variety of tumor cell lines suggests it may also be a valuable methylation biomarker in other tumor types.

    18. Discipline

      Epidemiology
      You have full text access to this OnlineOpen article
      Pulmonary tuberculosis increases the risk of lung cancer : A population-based cohort study (pages 618–624)

      Chen-Yi Wu, Hsiao-Yun Hu, Cheng-Yun Pu, Nicole Huang, Hsi-Che Shen, Chung-Pin Li and Yiing-Jeng Chou

      Article first published online: 30 SEP 2010 | DOI: 10.1002/cncr.25616

      Increased risk of lung cancer is associated with previous pulmonary tuberculosis infection.

    19. Pediatric Oncology
      You have free access to this content
      Twenty years of follow-up of survivors of childhood osteosarcoma : A report from the childhood cancer survivor study (pages 625–634)

      Rajaram Nagarajan, Anmmd Kamruzzaman, Kirsten K. Ness, Victoria G. Marchese, Charles Sklar, Ann Mertens, Yutaka Yasui, Leslie L. Robison and Neyssa Marina

      Article first published online: 4 OCT 2010 | DOI: 10.1002/cncr.25446

      Childhood osteosarcoma survivors do relatively well considering their extensive treatment, but they are at risk of experiencing chronic medical conditions and adverse health status. Survivors warrant life-long follow-up.

    20. You have full text access to this OnlineOpen article
      Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma (pages 635–641)

      Arnold C. Paulino, Ali Mazloom, Bin S. Teh, Michael South, M. Fatih Okcu, Jack Su, E. Brian Butler and Murali Chintagumpala

      Article first published online: 15 SEP 2010 | DOI: 10.1002/cncr.25601

      In this single-institution study, children with medulloblastoma were treated with craniospinal irradiation, intensity-modulated radiotherapy (IMRT) boost, and chemotherapy. Despite the volume reduction of normal brain and surrounding tumor bed structures that received high-dose IMRT, the 5-year local control rate was 90.5% ± 4.6%.

    21. Psychosocial Oncology
      You have full text access to this OnlineOpen article
      Suicide in patients with pancreatic cancer (pages 642–647)

      Kiran K. Turaga, Mokenge P. Malafa, Paul B. Jacobsen, Michael J. Schell and Michael G. Sarr

      Article first published online: 7 SEP 2010 | DOI: 10.1002/cncr.25428

      Suicide rates are 11 times greater in male patients with pancreatic adenocarcinoma and occur more frequently in patients who undergo operative interventions.

    22. Symptom Control and Palliative Care
      You have full text access to this OnlineOpen article
      Incidence and risk factors for lower alimentary tract mucositis after 1529 courses of chemotherapy in a homogenous population of oncology patients : Clinical and research implications (pages 648–655)

      Somashekar G. Krishna, Weizhi Zhao, Monica L. Grazziutti, Naveen Sanathkumar, Bart Barlogie and Elias J. Anaissie

      Article first published online: 22 SEP 2010 | DOI: 10.1002/cncr.25633

      Lower body surface area, renal function, and albumin are associated with increased risk for lower alimentary mucositis among a homogenous population of oncology patients undergoing sequential courses of chemotherapy including tandem melphalan-based autologous stem cell transplantation.

  6. Correspondence

    1. Top of page
    2. CancerScope
    3. Commentaries
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Correspondence
    1. You have full text access to this OnlineOpen article
    2. You have full text access to this OnlineOpen article

SEARCH

SEARCH BY CITATION